- Home
- THTX vs GUTS Comparison
THTX vs GUTS Comparison
Compare THTX & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- GUTS
- Stock Information
- Founded
- THTX 1993
- GUTS 2010
- Country
- THTX Canada
- GUTS United States
- Employees
- THTX N/A
- GUTS N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- THTX Health Care
- GUTS
- Exchange
- THTX Nasdaq
- GUTS NYSE
- Market Cap
- THTX 93.3M
- GUTS 110.1M
- IPO Year
- THTX N/A
- GUTS 2024
- Fundamental
- Price
- THTX $1.48
- GUTS $1.59
- Analyst Decision
- THTX Hold
- GUTS Buy
- Analyst Count
- THTX 1
- GUTS 2
- Target Price
- THTX N/A
- GUTS $10.00
- AVG Volume (30 Days)
- THTX 108.7K
- GUTS 411.9K
- Earning Date
- THTX 02-19-2025
- GUTS 02-10-2025
- Dividend Yield
- THTX N/A
- GUTS N/A
- EPS Growth
- THTX N/A
- GUTS N/A
- EPS
- THTX N/A
- GUTS N/A
- Revenue
- THTX $84,316,000.00
- GUTS $97,000.00
- Revenue This Year
- THTX $5.78
- GUTS N/A
- Revenue Next Year
- THTX $2.47
- GUTS N/A
- P/E Ratio
- THTX N/A
- GUTS N/A
- Revenue Growth
- THTX 5.75
- GUTS N/A
- 52 Week Low
- THTX $1.08
- GUTS $1.52
- 52 Week High
- THTX $2.18
- GUTS $11.55
- Technical
- Relative Strength Index (RSI)
- THTX 36.81
- GUTS 37.34
- Support Level
- THTX $1.42
- GUTS $1.77
- Resistance Level
- THTX $1.76
- GUTS $2.13
- Average True Range (ATR)
- THTX 0.09
- GUTS 0.14
- MACD
- THTX -0.05
- GUTS -0.00
- Stochastic Oscillator
- THTX 17.63
- GUTS 3.96
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.